Skyrizi (Risankizumab-rzaa)
- Medicine Name: Skyrizi
- API: Risankizumab-rzaa
- Dosage Form & Strength: Injection: 90 mg/mL, 150 mg/mL, 180 mg/1.2 mL, 360 mg/2.4 mL, and 600 mg/10 mL (60 mg/mL)
- Manufactured By: AbbVie Inc.
Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist used for the treatment and management of:
- moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
- active psoriatic arthritis (PsA) in adult patients.
- moderately to severely active Crohn’s disease (CD) in adults.
- moderately to severely active ulcerative colitis (UC) in adults.
Recommended Dosage:
Recommended Dosage for Plaque Psoriasis & Psoriatic Arthritis (PsA): The recommended dosage is 150 mg administered by subcutaneous (SC) injection at Week 0, Week 4, and every 12 weeks thereafter. In patients with psoriatic arthritis (PsA), this medicine can be administered alone or along with non-biologic disease-modifying antirheumatic drugs (DMARDs).
Recommended Dosage for Crohn’s Disease:
- Adult Patients- Induction: The recommended induction dosage is 600 mg administered by intravenous (IV) infusion over at least one hour at Week 0, Week 4, and Week 8.
- Adult Patients- Maintenance: The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous (SC) injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage required to maintain therapeutic response.
Recommended Dosage for Ulcerative Colitis:
- Adult Patients- Induction: The recommended induction dosage is 1,200 mg administered by intravenous (IV) infusion over at least two hours at Week 0, Week 4, and Week 8.
- Adult Patients- Maintenance: The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous (SC) injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage required to maintain therapeutic response.
In case a dose is missed or skipped, administer the dose of Skyrizi as promptly as possible. Thereafter, resume dosing at the regular scheduled time.
- It is possible to experience severe allergic reactions such as swelling, a rash, or difficulty in breathing after taking Risankizumab. If you have had any allergies in the past, inform your physician. If you develop any of the aforementioned signs, discontinue the medication and seek urgent assistance immediately.
- There are some symptoms like fever, chills, cough, and tiredness, which may indicate that your ability to fight off infections is being suppressed. If you feel unwell and have persistent infections before or during the treatment, inform your physician. Make sure to inform your physician about any symptoms you experience.
- Your risk of being infected with tuberculosis (TB) may rise as a result of taking Risankizumab. Ensure that you get a TB test done prior to starting treatment. Inform your physician if you have active TB currently or if you have had TB at some point. The healthcare provider may postpone or change their course of treatment based on the findings.
- Any type of vaccine that is live should be avoided during the treatment phase, which includes Risankizumab. Go over with your physician all the vaccines you have undergone. The effectiveness of certain vaccines could be lower while undergoing this treatment. During the treatment, inactive vaccines tend to be safer.
- Infrequently, but still a possibility, Risankizumab is known to have an impact on the liver and especially for people with Inflammatory Bowel Disease. Please pay attention to dark urine, yellowing of the eyes, or pain in your belly. While on this medication, your healthcare provider (HCP) might keep an eye on your liver at intervals.
- There is insufficient data on the effects of Risankizumab on pregnancy. If pregnancy is in consideration or already is, it is important to consult with a doctor in advance. This medication should only be used if necessary and under strict medical guidelines.
- No known information on Risankizumab and breastfeeding associations. Consult the doctor if planning to breastfeed. The physician will help in deciding whether to continue breastfeeding or discontinue breastfeeding while on this medication.
What documents are required to import SKYRIZI to India?
SKYRIZI (risankizumab-rzaa) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
How does the order get confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from the Doctor
- Import permit if applicable
Is SKYRIZI available in India?
SKYRIZI (risankizumab-rzaa injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input
- On availability of Skyrizi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
- On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
SKYRIZI can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of SKYRIZI (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Skyrizi 90 mg/mL, 150 mg/mL, 180 mg/1.2 mL price in India.
We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network can source SKYRIZI (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Skyrizi®?
What is the Manufacturer’s Name of Skyrizi®?
Is Skyrizi approved by the FDA?
What is the dosage and form of Skyrizi® supplied?
What are the most common side effects of Skyrizi® 90 mg/mL, 150 mg/mL, 180 mg/1.2 mL injections?
- Plaque Psoriasis and Psoriatic Arthritis: upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.
- Crohn’s Disease: back pain, upper respiratory infections, injection site reactions, headache, and arthralgia, arthralgia, abdominal pain, anemia, pyrexia, arthropathy, and urinary tract infection.
- Ulcerative Colitis: arthralgia, injection site reactions, arthralgia, pyrexia, and rash.
How much does Skyrizi® 90 mg/mL, 150 mg/mL, 180 mg/1.2 mL injection cost in India?
Can Skyrizi® 90 mg/mL, 150 mg/mL, 180 mg/1.2 mL injections be available in SAARC countries?
Is it safe to buy Skyrizi® 90 mg/mL, 150 mg/mL, 180 mg/1.2 mL injections online in India?
What are the storage conditions of Skyrizi® 90 mg/mL, 150 mg/mL, 180 mg/1.2 mL injections?
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.